^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TmMSTN-01
i
Other names: TmMSTN-01, anti-MSLN CAR T cell therapy, huCART-meso
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Gilead, University of Pennsylvania
Drug class:
Mesothelin-targeted CAR-T immunotherapy
Related drugs:
3ms
CAR T Cells in Mesothelin Expressing Cancers (clinicaltrials.gov)
P1, N=54, Completed, University of Pennsylvania | Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Jul 2024 | Trial primary completion date: Mar 2025 --> Nov 2023
Trial completion • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
PD-L1 (Programmed death ligand 1)
|
cyclophosphamide • TmMSTN-01
1year
CAR T Cells in Mesothelin Expressing Cancers (clinicaltrials.gov)
P1, N=65, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting | N=27 --> 65
Enrollment closed • Enrollment change • CAR T-Cell Therapy
|
PD-L1 (Programmed death ligand 1)
|
cyclophosphamide • TmMSTN-01
Share via
